Table 4

Independent determinants for LE in patients with Fabry disease with preserved LVEF

Spearman’s rP valuesOR* 95% CIP valuesAUC95% CIP values
Clinical marker
 NT-proBNP (pg/mL)†0.47<0.0011.851.18 to 2.920.0080.780.70 to 0.85<0.001
Echocardiographic markers
 IVSd (mm)0.55<0.0011.651.25 to 2.18<0.0010.820.75 to 0.89<0.001
 LVMI (g/m²)0.42<0.0011.031.01 to 1.050.0020.750.66 to 0.83<0.001
 EF (%)0.230.0061.050.97 to 1.130.2220.630.54 to 0.730.006
 LAVI (mL)0.39<0.0011.101.03 to 1.180.0040.730.64 to 0.82<0.001
 Septal E/e′0.60<0.0011.301.13 to 1.49<0.0010.860.79 to 0.92<0.001
 Lateral E/e′0.54<0.0011.341.11 to 1.620.0020.820.75 to 0.89<0.001
 Diastolic dysfunction grading0.56<0.0012.981.61 to 5.5260.0010.780.70 to 0.86<0.001
STI markers
 Global LS_sys (%)0.38<0.0011.161.00 to 1.340.0470.730.65 to 0.81<0.001
 E/LSr_E (cm)0.42<0.0011.031.00 to 1.050.0150.740.65 to 0.82<0.001
 Mid-lateral LS_sys (%)0.51<0.0011.201.07 to 1.340.0020.830.75 to 0.90<0.001
 Mid-lateral LSr_E (s−1)−0.44<0.0010.380.15 to 0.950.0340.760.68 to 0.84<0.001
  • *Adjusted for age, sex, BMI, NYHA functional class, GFR (DTPA).

  • †Ln transformed.

  • AUC, area under the curve; BMI, body mass index; E/e′, the ratio of early diastolic mitral inflow velocity to mitral annular tissue velocity; EF, ejection fraction; GFR (DTPA), glomerular filtration rate from 99mTc-diethylene triamine penta-acetic acid; IVSd, end-diastolic interventricular septal thickness; LAVI, left atrial volume indexed to body surface area; LE, late gadolinium enhancement; LS_sys, longitudinal systolic strain; LSr_E, longitudinal early diastolic strain rate; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass indexed to body surface area; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; STI, speckle-tracking imaging.